Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.66 |
| ▸ | HTR3B | O95264 | 4/20 | 0.66 |
| ▸ | HTR3A | P46098 | 4/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.66 |
| ▸ | LTA4H | P09960 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15703247 | 0.98 | ADRB1 (0.64) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5237290 | 0.94 | ADRB1 (0.58) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27416572 | 0.86 | ADRB1 (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5740819 | 0.86 | ADRB1 (0.67) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20000542 | 0.83 | MAPT (0.66) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7074380 | 0.82 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28261627 | 0.82 | ADRB1 (0.45) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4928979 | 0.81 | ADRB1 (0.69) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27617702 | 0.81 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7076503 | 0.81 | ADRB1 (0.59) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1897872-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
| CN-1760193-A | Antifungal compound of alkyl substitutional triazole class | NO 2 ARMY MEDICAL UNIV P L A (CN) | 2006-04-19 | — | — | CN | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | PARP1, PARP11, PARP2 | ADRB1 1258/4885HTR3E 2355/4885HTR3B 2429/4885 |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | ADRB1 88/4885HTR3E 1885/4885HTR3B 1122/4885 |
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | PPARA, PPARG, PPARD | ADRB1 110/4885HTR3E 3534/4885HTR3B 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.